Recently, Yichang Humanwell Pharmaceutical received the Drug Registration Certificate for its Hydrocodone-Ibuprofen Tablets, issued by the National Medical Products Administration. As the first generic version of the drug in China, it was approved under the Category 3 chemical drug classification and is recognized as having passed bioequivalence evaluation.

　　The introduction of this drug into market will significantly broadentreatment options for acute pain management in China, while also filling a critical gap in the domestic market. Patients with pain conditions now have access to a new therapeutic option.(Reporters/Wu Nan andWang Ying, Correspondents/Ren Shujuan andChen Ran)